Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I (a Phase 3 Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

• Published in: Open forum infectious diseases Vol. 4; no. suppl_1; p. S536
• Main Authors: Walsh, Thomas J, Bhowmick, Tanaya, Darouiche, Rabih, Zaitsev, Valerii, Giamarellos-Bourboulis, Evangelos, Shorr, Andrew F, Fedosiuk, Elena, File, Thomas M, Loutit, Jeffrey S, Lomovskaya, Olga, Dudley, Michael N, Perlin, David
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.10.2017
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofx163.1396

Abstract Background Meropenem-vaborbactam (M-V) is being developed for gram-negative infections, including complicated urinary tract infections (cUTIs) and multidrug-resistant bacterial infections. TANGO I was a Phase 3, multicenter, double-blind, randomized study of M-V vs. piperacillin-tazobactam (P-T) for treatment of adults with cUTI/acute pyelonephritis (AP). Superiority of M-V over P-T at the FDA primary endpoint has been reported. The effect of baseline MICs of Enterobacteriaceae to both study drugs and by susceptibility vs. non-susceptibility to P-T on clinical/microbiological outcome at end of intravenous treatment (EOIVT) was investigated. Methods MICs were conducted on baseline urinary isolates using CLSI methods. Susceptibility to P-T was defined as MIC ≤16 µg/mL (FDA/CLSI). Results Of 550 subjects randomized, 374 (68.0%) were included in m-MITT (165/192 [85.9%] in M-V and 154/182 [84.6%] in P-T groups had baseline Enterobactericeae). Mean duration of IV therapy was 8 days. Clinical outcomes were >90% across all MICs (Table 1). Conclusion At EOIVT, clinical cure and microbial eradication rates were >90% for both groups with no trend in responses according to baseline study drug MIC. M-V is highly active against Enterobacteriaceae in vitro and in patients, and is a potential new treatment option for cUTI/AP. Disclosures T. J. Walsh, The Medicines Company: Consultant and Investigator, Consulting fee and Research grant; Astellas: Consultant and Investigator, Consulting fee and Research grant; Allergan: Consultant and Investigator, Consulting fee and Research grant; Merck: Consultant and Investigator, Consulting fee and Research grant; A. F. Shorr, Astellas Pharma Global Development, Inc: Consultant and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; Cidara: Consultant, Consulting fee; Merck: Consultant, Scientific Advisor and Speaker’s Bureau, Research support and Speaker honorarium; T. M. File Jr., Allergan: Consultant, Consulting fee; Cempra: Consultant, Consulting fee; The Medicines Company: Consultant, Consulting fee; Merck: Consultant, Consulting fee; MotifBio: Consultant, Consulting fee; Pfizer: Consultant, Consulting fee; Paratek: Consultant, Consulting fee; Nabriva: Investigator, Research grant; J. S. Loutit, The Medicine’s Company: Employee and Shareholder, Salary; O. Lomovskaya, The Medicine’s Company: Employee and Shareholder, Salary; M. N. Dudley, The Medicine’s Company: Employee and Shareholder, Salary Table 1. Outcomes by Baseline MIC for Enterobacteriaceae at EOIVT (m-MITT) M-V P-T* MIC (µg/mL) Clinical Cure n/N’ (%) Microbial Eradication n/N’ (%) MIC (µg/mL) Clinical Cure n/N’ (%) Microbial Eradication n/N’ (%) ≤0.06 146/149 (98.0) 146/149 (98.0) ≤0.05 10/10 (100) 10/10 (100) 0.12 12/12 (100) 11/12 (91.7) 1 14/15 (93.3) 14/15 (93.3) 0.25 2/2 (100) 2/2 (100) 2 57/60 (95.0) 56/60 (93.3) 0.5 1/1 (100) 1/1 (100) 4 21/22 (95.5) 20/22 (90.9) 32 1/1 (100) 1/1 (100) 8 6/6 (100) 6/6 (100) 16 10/11 (90.9) 10/11 (90.9) 32 10/11 (90.9) 8/11 (72.7) 64 2/2 (100) 2/2 (100) >64 17/17 (100) 16/17 (94.1) Totals 162/165 (98.2) 161/165 (97.6) 147/154 (95.5) 142/154 (92.2) *FDA/CLSI non-susceptibility breakpoint of Enterobacteriaceae to P-T is >16 µg/mL Although 19.5% of baseline Enterobacteriaceae isolates were non-susceptible to P-T, clinical and microbiologic outcomes were similar for subjects with susceptible and non-susceptible isolates (p > 0.1).